A Study to Assess Long-term Safety, Tolerability, and Efficacy of Rocatinlimab in Adult and Adolescent Participants With Moderate-to-severe Atopic Dermatitis (AD)

Inclusion Criteria:

• Completion of an end of treatment duration visit (Week 24 or Week 52 visit for adultor adolescent studies, respectively) in a rocatinlimab parent study (ROCKET-IGNITE,ROCKET-HORIZON, ROCKET-SHUTTLE, ROCKET-ASTRO, ROCKET-ORBIT, OR ROCKET-VOYAGER)within the past 28 days.

• Participants from the parent study ROCKET-ORBIT must achieve an improvement in EASIscore at week 52 of at least 60% compared to parent study baseline (EASI 60).

Exclusion Criteria:

• Permanent investigational product discontinuation due to safety-related reasons,protocol-defined stopping rules or conditions/reasons unrelated to efficacy duringthe rocatinlimab parent study (ROCKET-IGNITE, ROCKET-HORIZON, ROCKET-SHUTTLE,ROCKET-ASTRO, ROCKET-ORBIT, OR ROCKET-VOYAGER), or at the time of Screening or Day